Relapsed or Refractory Angioimmunoblastic T cell Lymphoma research hub

ORACLE - Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T cell Lymphoma

This study is for people with a type of blood cancer called angioimmunoblastic T-cell lymphoma that has come back or not responded to previous treatment. It's testing a new oral medicine (a tablet) called azacitidine against standard treatments to see if it can stop the cancer from getting worse.